NMTRQ.US 9 Meters Biopharma Inc.

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 17, 2026
Market cap
USD 1.45K
P/E
-
P/B
4.58x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2023.

Is NMTRQ.US undervalued?

Graham number

The Graham number of 9 Meters Biopharma Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

9 Meters Biopharma Inc. fundamental analysis

No fundamental analysis for 9 Meters Biopharma Inc. yet.

9 Meters Biopharma Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About 9 Meters Biopharma Inc.

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity an…

Full company profile